PetVivo ends PrecisePRP agreement with VetStem

PetVivo has ended its commercial relationship with VetStem around the PrecisePRP product line, announcing on July 28, 2026 that the companies entered into a termination and settlement agreement effective July 24. According to PetVivo, the deal terminates the prior exclusive license and supply agreement, resolves outstanding claims between the parties, and sets terms for winding down inventory and related commercial activity. (globenewswire.com)

The move unwinds a partnership that was announced in February 2025 as a way for PetVivo to commercialize VetStem’s PrecisePRP canine and equine products. At the time, both companies positioned PrecisePRP as a first-in-class, off-the-shelf PRP option for veterinary use, emphasizing that it was freeze-dried, allogeneic, leucoreduced, and designed to avoid the blood draw and centrifugation workflow required by traditional PRP kits. VetStem’s own announcement described the arrangement as an exclusive license and supply agreement, while PetVivo framed it as an exclusive sales and marketing deal. (globenewswire.com)

PetVivo’s latest statement gives a clearer picture of the unwind. The company said all financial obligations under the prior agreement have been satisfied and extinguished except for payments expressly required under the settlement. PetVivo’s remaining obligation is an aggregate $75,000 in two scheduled cash payments, with a potential additional payment if an inventory reconciliation shows the transferred inventory falls below agreed minimum quantities. The remaining PrecisePRP inventory is to be returned to VetStem, and VetStem’s warrant to purchase 250,000 shares of PetVivo common stock remains in effect under its existing terms. (globenewswire.com)

There were signs this change was coming. In PetVivo’s fiscal 2026 results and related earnings-call coverage in late June 2026, the company said PrecisePRP sales contributed to revenue, but also noted that the VetStem arrangement carried lower gross margins than other parts of the business. Management also said at that time that it had entered negotiations for a transition agreement with VetStem. Separately, PetVivo has been signaling a broader strategic emphasis on its proprietary assets, including Spryng with OsteoCushion technology, and in June announced a merger agreement to acquire PiezoBioMembrane as part of a functional biomaterials platform strategy. (ebs.publicnow.com)

Public expert reaction appears limited so far. PetVivo CEO John Lai said the agreement lets both companies move forward independently and enables PetVivo to focus its resources on proprietary technologies, especially Spryng. VetStem had not surfaced a separate press release on the termination in the materials reviewed, although its site continues to present PrecisePRP as part of its PRP portfolio and its company history still lists the 2025 PetVivo agreement. That suggests VetStem may continue to position PrecisePRP directly, though that is an inference rather than an announced commercial plan. (globenewswire.com)

Why it matters: For veterinary professionals, the key issue is continuity, not a newly disclosed clinical concern. Nothing in the announcement points to a product recall, safety signal, or change in the underlying clinical rationale for PRP use. Instead, this is a channel and strategy shift involving a regenerative medicine product that had been marketed on convenience, standardization, and species-specific formulation for dogs and horses. Practices using PrecisePRP, or considering it, may need to confirm who is handling supply, training, and account support going forward. More broadly, the split is a reminder that commercial partnerships in veterinary orthobiologics can change quickly, even when the clinical category remains active. (globenewswire.com)

The business angle matters, too. PetVivo had already told investors that PrecisePRP was pressuring margins, which helps explain why the company might prefer to concentrate on products it controls more directly. For veterinarians, that could mean PetVivo’s field messaging shifts more heavily toward Spryng and away from third-party regenerative offerings, while VetStem may need to rebuild or reinforce its own go-to-market approach for PrecisePRP. Clinics that value off-the-shelf orthobiologics will likely watch whether VetStem maintains the same access and support without PetVivo as the intermediary. (benzinga.com)

What to watch: The next markers are a fuller SEC disclosure if filed, direct outreach from either company to veterinarians and distributors, and any evidence that VetStem is re-establishing standalone sales infrastructure for PrecisePRP while PetVivo reallocates resources toward Spryng and its broader biomaterials strategy. (globenewswire.com)